Arjun Natesan - Ultragenyx Vice Research
| RARE Stock | USD 44.24 0.39 0.89% |
Executive
Arjun Natesan is Vice Research of Ultragenyx
| Address | 60 Leveroni Court, Novato, CA, United States, 94949 |
| Phone | 415 483 8800 |
| Web | https://www.ultragenyx.com |
Ultragenyx Management Efficiency
The company has return on total asset (ROA) of (0.2343) % which means that it has lost $0.2343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9323) %, meaning that it created substantial loss on money invested by shareholders. Ultragenyx's management efficiency ratios could be used to measure how well Ultragenyx manages its routine affairs as well as how well it operates its assets and liabilities. As of April 29, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.49. At present, Ultragenyx's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 20.3 M, whereas Other Current Assets are projected to grow to (738.3 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| PharmD MBA | Incyte | 66 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Francis Burrows | Kura Oncology | N/A | |
| Xiaolin Wang | Revolution Medicines | 53 | |
| Soojin Kim | Inozyme PharmaInc | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Lauren Wood | PDS Biotechnology Corp | N/A | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Evan MBA | Alnylam Pharmaceuticals | N/A | |
| Adam Townsend | Apellis Pharmaceuticals | 46 | |
| Ian Taylor | Arvinas | 61 | |
| John Grosso | Arvinas | 67 | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| JD Esq | Kura Oncology | 53 | |
| David Mantus | X4 Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -1.93 | ||||
| Return On Asset | -0.23 |
Ultragenyx Leadership Team
Elected by the shareholders, the Ultragenyx's board of directors comprises two types of representatives: Ultragenyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ultragenyx. The board's role is to monitor Ultragenyx's management team and ensure that shareholders' interests are well served. Ultragenyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ultragenyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Pinion, Chief Quality Operations Officer and Senior Vice President Analytical Sciences and Research | ||
| Karah Parschauer, Executive Vice President General Counsel | ||
| Shalini Sharp, CFO and Sr. VP | ||
| Daniel Welch, Director | ||
| Camille Bedrosian, Chief Medical Officer and Executive Vice President | ||
| Dennis Huang, Chief Technical Operations Officer and Sr. VP | ||
| Lars Ekman, Independent Director | ||
| Alison Skrinar, Vice Evaluation | ||
| Emil Kakkis, President CEO, Board Member | ||
| Jayson Dallas, Senior Vice President Chief Commercial Officer | ||
| Danielle Keatley, Senior Communications | ||
| Samuel Wadsworth, Chief Therapy | ||
| Ernie Meyer, Chief VP | ||
| Karah JD, Chief Affairs | ||
| John II, Chief Sciences | ||
| Deborah Dunsire, Independent Director | ||
| Michael Narachi, Director | ||
| Howard Horn, Executive CFO | ||
| Arjun Natesan, Vice Research | ||
| Vimal Srivastava, Senior Management | ||
| Sunil Agarwal, Chief Medical Officer, Senior Vice President | ||
| Aaron Olsen, Senior Finance | ||
| Paul JD, Vice Property | ||
| Theodore Huizenga, Corporate VP | ||
| Erik Harris, Executive Vice President and Chief Commercial Officer | ||
| Camille MD, Chief VP | ||
| Matthew Fust, Independent Director | ||
| Shehnaaz Suliman, Independent Director | ||
| Clay Siegall, Independent Director | ||
| Thomas Kassberg, Chief Bus. Officer and Sr. VP | ||
| Eric MD, Chief VP | ||
| William Aliski, Independent Director | ||
| Wladimir Hogenhuis, COO |
Ultragenyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ultragenyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.93 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.40) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | 4 B | ||||
| Shares Outstanding | 82.34 M | ||||
| Shares Owned By Insiders | 4.10 % | ||||
| Shares Owned By Institutions | 95.90 % | ||||
| Number Of Shares Shorted | 4.38 M | ||||
| Price To Earning | (6.90) X |
Ultragenyx Investors Sentiment
The influence of Ultragenyx's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ultragenyx. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Ultragenyx's public news can be used to forecast risks associated with an investment in Ultragenyx. The trend in average sentiment can be used to explain how an investor holding Ultragenyx can time the market purely based on public headlines and social activities around Ultragenyx. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ultragenyx's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ultragenyx's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ultragenyx's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ultragenyx.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ultragenyx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ultragenyx's short interest history, or implied volatility extrapolated from Ultragenyx options trading.
Currently Active Assets on Macroaxis
When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Ultragenyx Stock analysis
When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Ultragenyx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.25) | Revenue Per Share 5.905 | Quarterly Revenue Growth 0.233 | Return On Assets (0.23) | Return On Equity (1.93) |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.